Fibronectin 1 (FN1) was significantly upregulated in myocardial tissue of sudden death from coronary heart disease cases and downregulated in serum of anaphylaxis models, while GP1BA and PF4 were upregulated in SD-CHD but downregulated or unchanged in ASD, providing a biomarker panel discriminating anaphylactic sudden death from cardiac sudden death.
Does proteomic profiling identify biomarkers that can discriminate anaphylactic sudden death from sudden death due to coronary heart disease?
Proteomic profiling identifies FN1, GP1BA, and PF4 as candidate biomarkers to forensically distinguish anaphylactic sudden death from coronary heart disease sudden death.
To address the forensic diagnostic challenge of distinguishing Anaphylactic Sudden Death (ASD) from Sudden Death from Coronary Heart Disease (SD-CHD), this study established Ldlr−/− mouse models of Atherosclerosis (AS) and ovalbumin-induced Anaphylaxis (AP). LC-MS/MS-based serum proteomic analysis of Atherosclerosis (AS) and Anaphylaxis (AP) mice identified fibronectin 1 (FN1), platelet glycoprotein Ibα chain (GP1BA), and platelet factor 4 (PF4) as candidate biomarkers. These candidates were validated by parallel reaction monitoring (PRM), enzyme-linked immunosorbent assay (ELISA), and immunohistochemistry (IHC) in a combined AS + AP mouse model and in post-mortem human cardiac and bronchiolar epithelial tissue. In mice, serum FN1, GP1BA, and PF4 levels were significantly elevated in the AS group, whereas only FN1 was markedly downregulated in AP mice. In human tissues, FN1, GP1BA, and PF4 were all upregulated in Sudden death from coronary heart disease (SD-CHD) myocardial samples, with FN1 showing the greatest increase. In airway epithelium, FN1 was upregulated in anaphylactic sudden death (ASD) and anaphylactic sudden death (ASD) with Coronary Atherosclerosis (ASD + CAS) groups, while GP1BA was downregulated. These results indicate that FN1 serves as a key differential mouse serum biomarker, while PF4 and GP1BA aid in Sudden death from coronary heart disease (SD-CHD) diagnosis. Collectively, this multimarker, multilevel framework provides a molecular diagnostic strategy for the forensic identification of complex sudden death.
Fan et al. (Wed,) conducted a other in Adult sudden death cases including those due to anaphylactic sudden death (ASD) and sudden death from coronary heart disease (SD-CHD) (n=80). None (Observational biomarker discovery and validation study) vs. Comparison between groups: ASD vs. SD-CHD vs. ASD + CAS vs. Control was evaluated on Differential expression levels of candidate serum and tissue biomarkers (FN1, GP1BA, PF4) capable of discriminating anaphylactic sudden death from sudden death due to coronary heart disease. Fibronectin 1 (FN1) was significantly upregulated in myocardial tissue of sudden death from coronary heart disease cases and downregulated in serum of anaphylaxis models, while GP1BA and PF4 were upregulated in SD-CHD but downregulated or unchanged in ASD, providing a biomarker panel discriminating anaphylactic sudden death from cardiac sudden death.